&Partners’s Axsome Therapeutics AXSM Stock Holding History

&Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47M	Sell	5,994 -143	-2%	-$31K	0.01%	1196
2026 Q1	$1.04M	Buy	6,137 +4,535	+283%	+$783K	0.01%	1278
2025 Q4	$293K	Buy	+1,602	New	+$224K	﹤0.01%	1925

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

&Partners's AXSM Position: Q2 2026 in Review

&Partners reduced its Axsome Therapeutics (AXSM) stake by 2.3% in Q2 2026, selling an estimated $31K and leaving 5,994 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #1196.

&Partners first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

&Partners held 5,994 shares of Axsome Therapeutics worth $1.47M as of Q2 2026.
&Partners sold 143 Axsome Therapeutics shares in Q2 2026, an estimated $31K.
Axsome Therapeutics made up 0.01% of &Partners's portfolio in Q2 2026, its #1196 holding.
&Partners first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.